Results 121 to 130 of about 61,149 (183)

Ο ρόλος των μοριακών δεικτών DEK, SURVIVIN, P33ING1, MMP-2, C-ERBB-2 στην πρόγνωση του ουροθηλιακού καρκινώματος της ουροδόχου κύστεως

, 2010
Λάζαρος Σκάγιας
openalex   +2 more sources

Clinical significance of serum factors relating to ERBB signal pathways in a phase II trial of S-1 plus cisplatin combined with trastuzumab for HER2-positive advanced gastric or esophagogastric junction cancer: WJOG7212G (T-SPACE) TR study [PDF]

, 2016
Yasutaka Sukawa, Katsuhiko Nosho, Yuji Miura, Toshimi Takano, Miki Ito, Kimio Yonesaka, M. Mori, Shinya Tokunaga, Jun‐ichi Kawada, Hiroyuki Okuda, Tohru Sakamoto, Yoshinori Hirashima, K. Uchino, Yoshinori Miyata, Kenichi Yoshimura, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Ichinosuke Hyodo, Kei Muro   +19 more
openalex   +1 more source

PanERBB CAR T-cells: Shifting gears toward a cure for fanconi anemia head/neck cancers. [PDF]

Mol Ther Oncol
Wiek C, Hüsken S, Scheckenbach K, Eikelberg I, Niktoreh N, Hanenberg H.   +5 more
europepmc   +1 more source

Phosphoproteomic analysis reveals the diversity of signaling behind ErbB-inhibitor-induced phenotypes. [PDF]

FEBS J
Vaparanta K, Song Z, Farahani I, Jokilammi A, Merilahti J, Örling J, Virtanen N, Haapaniemi P, Sahlgren C, Elenius K, Paatero I.   +10 more
europepmc   +1 more source

Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 [PDF]

, 2013
Ruth Maron, Bilha Schechter, Maicol Mancini, Georg Mahlknecht, Yosef Yarden, Michael Sela   +5 more
openalex   +1 more source

ErbB signaling and cell cycle pathways associated with trastuzumab deruxtecan resistance in HER2-positive metastatic breast cancer: a case report. [PDF]

AME Case Rep
Gao HF, Lin YY, Lv XZ, Li H, Xu FP, Wang K.   +5 more
europepmc   +1 more source

Regulation Mechanism of ErbB-Hergulin Interaction Shown by Single-molecule Kinetic Analysis in Living Cells

, 2013
Michio Hiroshima, Yasushi Sako
openalex   +2 more sources

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel [PDF]

, 2012
Shazad Q. Ashraf, Angela M. Nicholls, Jennifer L. Wilding, Triantafyllia Ntouroupi, Neil Mortensen, Walter F. Bodmer   +5 more
openalex   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway. [PDF]

Cell Death Dis
Li C, Shi S, Li L, Wang Y, Yao M, Yu C, Yu C, Xie C.   +7 more
europepmc   +1 more source